QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER
Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) — QSAM Biosciences, Inc. (OTCQB:QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).
Related news for (QSAM)
- QSAM Biosciences Signs Definitive Agreement to be Acquired by Telix Pharmaceuticals
- QSAM Biosciences Signs Term Sheet to be Acquired by Telix Pharmaceuticals; Receives $2 Million Pre-Closing Collaboration and Option Fee
- QSAM Biosciences Provides Update to Shareholders on Phase 1 Progress and Preliminary Clinical Data
- QSAM Biosciences Expands its Study of CycloSam® in the Treatment of Bone Cancer; Opens Patient Enrollment at Key Chicago Center, Insight Hospital and Medical Center